ストックスクリーナーアプリを入手
29.86
5.03%
1.43
前日終値:
$28.43
開ける：
$28.76
24時間の取引高:
450.32K
Relative Volume:
0.32
時価総額：
$1.34B
収益：
-
当期純損益:
$-47.20M
株価収益率:
-19.08
EPS:
-1.5653
ネットキャッシュフロー:
$-43.65M
1週間 パフォーマンス:
-6.60%
1か月 パフォーマンス:
+21.38%
6か月 パフォーマンス:
+178.54%
1年 パフォーマンス:
+45.66%
1日の値動き範囲:
$27.93
$30.05
1週間の範囲:
$27.86
$33.31
52週間の値動き範囲:
$4.8069
$34.83
Mbx Biosciences Inc Stock (MBX) Company Profile
MBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
29.86 | 1.28B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | 開始されました | Goldman | Sell |
| 2025-11-04 | 開始されました | TD Cowen | Buy |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-08-15 | 再開されました | Jefferies | Buy |
| 2025-08-05 | 開始されました | Mizuho | Outperform |
| 2025-07-16 | 開始されました | Oppenheimer | Outperform |
| 2025-04-10 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
すべてを表示
Mbx Biosciences Inc (MBX) 最新ニュース
EcoR1 Capital LLC Lowers Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences (NASDAQ:MBX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Walleye Capital LLC Increases Stock Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains - Seeking Alpha
MBX Biosciences, Inc. $MBX Stake Increased by Stempoint Capital LP - MarketBeat
MBX Biosciences (NASDAQ:MBX) Shares Down 5.6%Should You Sell? - MarketBeat
Certain Common Stock of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Stock Options of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Goldman Sachs initiates coverage of MBX Biosciences (MBX) with sell recommendation - MSN
Goldman Sachs Initiates Coverage of MBX Biosciences (MBX) with Sell Recommendation - Nasdaq
MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM ExitWhat's Changed - Yahoo Finance
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns - Investing.com Nigeria
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns By Investing.com - Investing.com South Africa
MBX Biosciences drops 4% in premarket trading after Goldman initiates with sell - MSN
MBX Biosciences initiated with a sell at Goldman Sachs - MSN
Goldman Sachs Initiates Coverage on MBX with Sell Rating | MBX S - GuruFocus
Goldman Sachs Initiates Coverage on MBX Biosciences With Sell Rating, $18 Price Target - marketscreener.com
MBX Biosciences initiated with a Sell at Goldman Sachs - TipRanks
Is MBX Biosciences Inc. stock attractive for growth ETFsJuly 2025 News Drivers & Technical Analysis for Trade Confirmation - Newser
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones - Nasdaq
Sio Capital Management LLC Acquires New Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
How MBX Biosciences Inc. stock benefits from global expansionGold Moves & Growth Focused Stock Pick Reports - Newser
MBX Biosciences (MBX) Stock Analysis Report | Financials & Insights - Benzinga
MBX Biosciences (NASDAQ:MBX) Sets New 12-Month HighHere's What Happened - MarketBeat
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus - MSN
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% - MSN
MBX Biosciences, Inc. $MBX Shares Purchased by Franklin Resources Inc. - MarketBeat
Rockefeller Capital Management L.P. Acquires Shares of 34,135 MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences (NASDAQ:MBX) Trading Up 5.6%Should You Buy? - MarketBeat
MBX S-8 & SEC Filings - Yahoo Finance Australia
MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide - MSN
Mbx biosciences stock reaches all-time high at 32.16 USD - Investing.com
Mbx biosciences stock reaches all-time high at 32.16 USD By Investing.com - Investing.com Australia
MBX: Once-monthly obesity candidate MBX 4291 shows strong potential for best-in-class tolerability and efficacy - TradingView
Will MBX Biosciences Inc. stock outperform tech sector in 2025Earnings Miss & Low Risk High Reward Ideas - newser.com
Is MBX Biosciences Inc. stock a safe buy before earningsSell Signal & Precise Swing Trade Entry Alerts - newser.com
Will MBX Biosciences Inc. stock rally after Fed decisionsTrade Risk Report & AI Enhanced Trade Execution Alerts - newser.com
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
MBX Biosciences stock maintains Buy rating at Jefferies on strong Phase 2 data By Investing.com - Investing.com South Africa
MBX Biosciences stock maintains Buy rating at Jefferies on strong Phase 2 data - Investing.com Nigeria
Can MBX Biosciences Inc. stock resist sector downturns - newser.com
Will MBX Biosciences Inc. stock remain a Wall Street favorite2025 Technical Patterns & Risk Controlled Daily Trade Plans - newser.com
MBX: Strong clinical progress and funding position drive multiple catalysts in endocrine and metabolic pipeline - TradingView
MBX: Strong clinical progress and funding drive late-stage catalysts in endocrine and metabolic programs - TradingView
Mbx Biosciences Inc (MBX) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):